NATANEA CATALYST - The morning phase of the NATANEA Protocol.

Sirtuins are a family of seven enzymes (SIRT1 through SIRT7) that act as cellular sensors of metabolic health. They influence mitochondrial biogenesis, DNA repair, inflammatory regulation, and oxidative-stress response — all four of which shape the biological environment in which oocytes mature.

Sirtuins do not work in isolation. They depend on a single coenzyme — NAD⁺ (nicotinamide adenine dinucleotide) — as their obligatory fuel. When NAD⁺ is abundant, sirtuin activity is supported; when NAD⁺ falls, that activity falls with it. NAD⁺ also powers the mitochondria directly, supplying the ATP that oocyte maturation depends on.

This is where β-Nicotinamide Mononucleotide (NMN) fits. NMN is a direct biochemical precursor to NAD⁺ — the body converts it into NAD⁺ through a single enzymatic step. Published reproductive research has documented that ovarian and oocyte NAD⁺ levels decline with reproductive age, and that this decline tracks alongside the decline in oocyte quality.

This is not a claim that CATALYST does any of those things in your body. It is a description of the biological pathway the formulation was designed to support — a distinction we take seriously.

Many sirtuin-adjacent supplements are lipophilic — fat-soluble compounds whose absorption is inconsistent, heavily dependent on dietary fat, and largely lost to first-pass metabolism in the liver. NMN is a different kind of molecule.

NMN is water-soluble. It does not require a fat-soluble delivery vehicle, and its chemistry is well suited to oral supplementation. Research has also described a dedicated NMN transporter, Slc12a8, that allows cells to take up NMN directly and convert it into NAD⁺ — a route that is specific to NMN and not shared by fat-soluble polyphenols.

• Solubility. Being water-soluble, NMN does not depend on a fatty meal or a phospholipid-complex formulation to be absorbed.
• Direct uptake. The Slc12a8 transporter provides a dedicated cellular route for NMN, distinct from the membrane-crossing problem faced by lipophilic compounds.
• A single-step conversion. Once inside the cell, NMN is converted to NAD⁺ enzymatically — the coenzyme that fuels sirtuin activity and mitochondrial energy production.

Because the absorption problem is fundamentally different from fat-soluble polyphenols, the priorities for CATALYST are dose, purity, and timing — not fat-based bioavailability engineering.

CATALYST delivers 500 mg of β-Nicotinamide Mononucleotide as a single morning dose. It is the active layer of the protocol — taken alongside the evening NATANEA botanicals across a 90-day window.

We are deliberate about how we frame this dose. The human reproductive research on NMN is still early: most of it has examined IVF/IVM and diminished-ovarian-reserve settings rather than everyday preconception support, and the most robust mechanistic data remain animal studies. We therefore position 500 mg as a consistent daily oral dose intended to support NAD⁺ levels in the preconception window — a structure-function role — not as a clinically-proven fertility dose.

This is also why CATALYST is sold only inside the NATANEA Protocol, and only with a clear instruction to stop at a positive pregnancy test and consult your healthcare provider: fetal-safety data for NMN are insufficient.

NAD⁺ is not constant across the 24-hour cycle. Its synthesis and its demand follow a daily rhythm tied to the sleep–wake and feeding cycle, and the waking, active phase is when NAD⁺-dependent energy metabolism is most in demand.

Taking CATALYST in the morning serves two simple purposes:

• It aligns NAD⁺ replenishment with the waking-phase demand, rather than the overnight window covered by the evening botanicals.
• It pairs cleanly with the evening dose of NATANEA, so the two phases of the protocol map onto the two halves of the day.

And because NMN is water-soluble, the morning dose does not need to be taken with a fat-containing meal — a practical contrast with lipophilic polyphenols. This is why CATALYST is structured as the morning half of an indivisible two-phase protocol, not as a "take whenever" supplement.